✦ LIBER ✦

Safety, Pharmacokinetic, and Pharmacodynamic Profiles of Ipragliflozin (ASP1941), a Novel and Selective Inhibitor of Sodium-Dependent Glucose Co-Transporter 2, in Patients with Type 2 Diabetes Mellitus

✍ Scribed by Schwartz, Sherwyn L.; Akinlade, Bola; Klasen, Sally; Kowalski, Donna; Zhang, Wenhui; Wilpshaar, Wim

Book ID: 120519401
Publisher: Mary Ann Liebert
Year: 2011
Tongue: English
Weight: 322 KB
Volume: 13
Category: Article
ISSN: 1520-9156
DOI: 10.1089/dia.2011.0012

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Effect of Ipragliflozin (ASP1941), a Nov

Effect of Ipragliflozin (ASP1941), a Novel Selective Sodium-Dependent Glucose Co-Transporter 2 Inhibitor, on Urinary Glucose Excretion in Healthy Subjects

✍ Dr Stephan A. Veltkamp, Takeshi Kadokura, Walter J. J. Krauwinkel, Ronald A. Smu 📂 Article 📅 2011 🏛 Springer International Publishing AG 🌐 English ⚖ 188 KB

Pharmacokinetics and Pharmacodynamics of

Pharmacokinetics and Pharmacodynamics of Canagliflozin, a Sodium Glucose Co-Transporter 2 Inhibitor, in Subjects With Type 2 Diabetes Mellitus

✍ Devineni, Damayanthi; Curtin, Christopher R.; Polidori, David; Gutierrez, Maria 📂 Article 📅 2013 🏛 Sage Publications 🌐 English ⚖ 605 KB

Pharmacokinetics and pharmacodynamics of

Pharmacokinetics and pharmacodynamics of dapagliflozin, a novel selective inhibitor of sodium–glucose co-transporter type 2, in Japanese subjects without and with type 2 diabetes mellitus

✍ S. Kasichayanula; M. Chang; M. Hasegawa; X. Liu; N. Yamahira; F. P. LaCreta; Y. 📂 Article 📅 2011 🏛 John Wiley and Sons 🌐 English ⚖ 705 KB

Clinical Pharmacokinetics and Pharmacody

Clinical Pharmacokinetics and Pharmacodynamics of Dapagliflozin, a Selective Inhibitor of Sodium-Glucose Co-transporter Type 2

✍ Kasichayanula, Sreeneeranj; Liu, Xiaoni; LaCreta, Frank; Griffen, Steven C.; Bou 📂 Article 📅 2013 🏛 Springer International Publishing AG 🌐 English ⚖ 522 KB

Remogliflozin etabonate, a selective inh

Remogliflozin etabonate, a selective inhibitor of the sodium-dependent transporter 2 reduces serum glucose in type 2 diabetes mellitus patients

✍ R. L. Dobbins; R. O’Connor-Semmes; A. Kapur; C. Kapitza; G. Golor; I. Mikoshiba; 📂 Article 📅 2011 🏛 John Wiley and Sons 🌐 English ⚖ 612 KB

Safety, pharmacokinetics and pharmacodyn

Safety, pharmacokinetics and pharmacodynamics of remogliflozin etabonate, a novel SGLT2 inhibitor, and metformin when co-administered in subjects with type 2 diabetes mellitus

✍ Elizabeth K Hussey, Anita Kapur, Robin O’Connor-Semmes… 📂 Article 📅 2013 🏛 Springer (Biomed Central Ltd.) 🌐 English ⚖ 291 KB